6
total announcements
544738.BO · 15 min delayed
Speciality Medicines Ltd
Speciality Medicines Ltd has submitted its annual report for FY 2025-26, as per Regulation 34(1) of SEBI's Listing Obligations and Disclosures requirements.
Speciality Medicines Ltd
Speciality Medicines Ltd has submitted a notice for its 5th Annual General Meeting (AGM) to be held on September 28, 2026, through Video Conferencing (VC) or Other Audio-Visual Means (OAVM). The meeting will consider and adopt the audited financial statement for the financial year ended March 31, 2026, and the reports of the Board of Directors and Auditors. The company also seeks re-appointment of Mr. Sumit Babubhai Goyani as a Director.
Speciality Medicines Ltd
Speciality Medicines Ltd has announced the outcome of its board meeting held on September 03, 2026, where the board approved the draft directors' report for the financial year 2025-26, decided to call the 5th Annual General Meeting on September 28, 2026, and appointed a remote e-voting agency and a scrutinizer.
Speciality Medicines Ltd
Speciality Medicines Ltd has received regulatory approval from the competent health authority in Ethiopia for two additional speciality pharmaceutical formulations, Olanzapine Tablets 5 mg and Diazepam Tablets 5 mg, taking its total registered product portfolio in the Ethiopian market to 12 formulations.
Speciality Medicines Ltd
Speciality Medicines Ltd has received regulatory approval for two new products in Ethiopia, strengthening its presence in the African region and expanding its speciality portfolio across international markets.
Speciality Medicines Ltd
Speciality Medicines Ltd has appointed Capital Bridge Advisory Service Private Limited as its Investor and Public Relations Agency, enhancing its investor relations and capital market communication efforts.